| 摘要 |
The present invention provides a nucleic acid encoding IFN- alpha fusion proteins. The specification also describes the proteins encoded by said nucleic acids, methods of making IFN- alpha fusion proteins and methods of utilizing the compounds for the treatment of cancer. One specific IFN- alpha fusion protein comprising IFN- alpha or a portion thereof capable of enhancing the killing ability of an effector cell and an anti-CD20 antibody, such as RITUXAN®, which can target, for example, B cell lymphomas <i>e.g.</i>, non-Hodgkin's lymphoma).
|
